OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MERCN$21.5056

Mercan Kimya Sanayi ve Ticaret AS

Commodity ChemicalsVerified

Mercan Kimya has a market capitalization of 3.85 billion TRY and a price-to-earnings ratio of 91.46, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 2.54, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 42.36, which is significantly higher than the typical range for the commodity chemicals industry, indicating potential overvaluation or high expectations for future earnings. In terms of profitability, Mercan Kimya's return on equity is 2.78%, and its return on assets is 1.66%. These figures are below the industry median for commodity chemicals, suggesting that the company is not generating returns as efficiently as its peers. The company's operating margin is 12.27% (calculated from operating income of 107.2 million TRY on revenue of 874.2 million TRY), which is also below the industry median, indicating that the company is facing cost pressures or pricing challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's operations are primarily based in Turkey, and it is exposed to local currency and regulatory risks. Looking at the company's growth trajectory, Mercan Kimya's revenue is expected to remain relatively flat in the current fiscal year, with a marginal increase in the next fiscal year. The company's capital expenditures are negative, indicating that it is not investing in new projects or capacity expansion, which may limit its long-term growth potential. The company's free cash flow is 18.35 million TRY, which is insufficient to cover its capital expenditures, suggesting that it may need to seek external financing for future investments. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The company has a debt-to-equity ratio of 0.5, which is relatively low, but its net cash position is negative after subtracting total debt, indicating that it has more debt than cash. The company's liquidity risk is further exacerbated by its low free cash flow and the absence of a clear capital allocation strategy. The company has not issued new shares in the recent past, and there is no indication of imminent dilution. Recent events related to Mercan Kimya include the publication of its latest financial statements, which show a decline in net income compared to the previous year. The company has not issued any significant press releases or held earnings calls in the recent past, and there is no indication of major strategic changes or new product launches. The company's financial performance is closely tied to the global commodity chemicals market, and it is exposed to fluctuations in raw material prices and demand.

30-day price · MERCN+8.80 (+54.3%)
Low$15.80High$27.38Close$25.00As of12 May, 00:00 UTC
Profile
CompanyMercan Kimya Sanayi ve Ticaret AS
TickerMERCN.IS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Mercan Kimya Sanayi ve Ticaret AS is a Turkish company engaged in the production and trade of chemicals, operating within the commodity chemicals industry.

Classification. Mercan Kimya is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a classification confidence of 0.92.

Mercan Kimya has a market capitalization of 3.85 billion TRY and a price-to-earnings ratio of 91.46, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 2.54, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is 42.36, which is significantly higher than the typical range for the commodity chemicals industry, indicating potential overvaluation or high expectations for future earnings. In terms of profitability, Mercan Kimya's return on equity is 2.78%, and its return on assets is 1.66%. These figures are below the industry median for commodity chemicals, suggesting that the company is not generating returns as efficiently as its peers. The company's operating margin is 12.27% (calculated from operating income of 107.2 million TRY on revenue of 874.2 million TRY), which is also below the industry median, indicating that the company is facing cost pressures or pricing challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's operations are primarily based in Turkey, and it is exposed to local currency and regulatory risks. Looking at the company's growth trajectory, Mercan Kimya's revenue is expected to remain relatively flat in the current fiscal year, with a marginal increase in the next fiscal year. The company's capital expenditures are negative, indicating that it is not investing in new projects or capacity expansion, which may limit its long-term growth potential. The company's free cash flow is 18.35 million TRY, which is insufficient to cover its capital expenditures, suggesting that it may need to seek external financing for future investments. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The company has a debt-to-equity ratio of 0.5, which is relatively low, but its net cash position is negative after subtracting total debt, indicating that it has more debt than cash. The company's liquidity risk is further exacerbated by its low free cash flow and the absence of a clear capital allocation strategy. The company has not issued new shares in the recent past, and there is no indication of imminent dilution. Recent events related to Mercan Kimya include the publication of its latest financial statements, which show a decline in net income compared to the previous year. The company has not issued any significant press releases or held earnings calls in the recent past, and there is no indication of major strategic changes or new product launches. The company's financial performance is closely tied to the global commodity chemicals market, and it is exposed to fluctuations in raw material prices and demand.
Key takeaways
  • Mercan Kimya is overvalued based on its high price-to-earnings and enterprise value to EBITDA ratios.
  • The company's profitability metrics are below the industry median, indicating inefficiencies in cost management and pricing.
  • The company's revenue is concentrated in a single segment and geographic region, increasing its exposure to local risks.
  • The company's growth is limited by its lack of capital expenditures and insufficient free cash flow.
  • The company has a medium liquidity risk and a low dilution risk, but its net cash position is negative.
  • The company's recent financial performance shows a decline in net income, and there are no indications of major strategic changes.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTRY
Revenue$874.2M
Gross profit$199.9M
Operating income$107.2M
Net income$42.1M
R&D
SG&A
D&A
SBC
Operating cash flow$145.3M
CapEx-$41.4M
Free cash flow$18.3M
Total assets$2.53B
Total liabilities$1.01B
Total equity$1.51B
Cash & equivalents$64.3M
Long-term debt$756.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$665.8M$133.4M$121.6M$82.4M
FY-3$2.84B$424.3M$101.5M$77.9M
FY-2$3.48B$392.9M$87.8M-$129.6M
FY-1$3.44B$337.4M-$78.4M-$134.6M
FY0$2.90B$551.5M$141.9M$74.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$668.7M$357.9M$8.7M
FY-3$2.08B$1.22B$117.2M
FY-2$3.35B$1.89B$93.2M
FY-1$3.55B$2.34B$71.4M
FY0$3.92B$2.44B$73.1M
PeriodOCFCapExFCFSBC
FY-4-$101.8M-$47.1M$82.4M
FY-3-$82.2M-$63.1M$77.9M
FY-2$93.1M-$258.1M-$129.6M
FY-1$666.2M-$121.1M-$134.6M
FY0$7.3M-$123.2M$74.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$874.2M$107.2M$42.1M$18.3M
FQ-6$665.6M$102.1M-$130.8M-$133.5M
FQ-5$613.3M$20.4M-$76.2M-$129.2M
FQ-4$1.55B$143.0M$67.3M$118.3M
FQ-3$629.9M$107.7M$24.5M-$14.4M
FQ-2$645.4M$68.7M$39.2M-$10.5M
FQ-1$681.0M$199.8M$31.9M
FQ0$848.3M$162.1M$99.4M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.53B$1.51B$64.3M
FQ-6$2.56B$1.52B$42.8M
FQ-5$2.73B$1.60B$45.0M
FQ-4$3.55B$2.34B$71.4M
FQ-3$3.14B$2.00B$99.7M
FQ-2$3.46B$2.09B$82.3M
FQ-1$3.68B$2.25B$76.9M
FQ0$3.92B$2.44B$73.1M
PeriodOCFCapExFCFSBC
FQ-7$145.3M-$41.4M$18.3M
FQ-6$340.4M-$64.8M-$133.5M
FQ-5$758.3M-$133.5M-$129.2M
FQ-4$666.2M-$121.1M$118.3M
FQ-3$135.8M-$65.6M-$14.4M
FQ-2$66.5M-$124.7M-$10.5M
FQ-1
FQ0$7.3M-$123.2M
Valuation
Market price$21.50
Market cap$3.85B
Enterprise value$4.54B
P/E91.5
Reported non-GAAP P/E
EV/Revenue5.2
EV/Op income42.4
EV/OCF31.2
P/B2.5
P/Tangible book2.5
Tangible book$1.51B
Net cash-$691.9M
Current ratio1.2
Debt/Equity0.5
ROA1.7%
ROE2.8%
Cash conversion3.5%
CapEx/Revenue-4.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricMERCNActivity
Op margin12.3%5.5% medp25 -0.0% · p75 10.8%top quartile
Net margin4.8%4.1% medp25 0.1% · p75 8.8%above median
Gross margin22.9%20.5% medp25 12.4% · p75 29.7%above median
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-4.7%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity50.0%37.1% medp25 10.3% · p75 82.0%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 08:39 UTC#cea4eac0
Market quoteclose TRY 23.80 · shares 0.18B diluted
no public URL
2026-05-04 00:21 UTC#6602b03a
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 13:28 UTCJob: aba97e20